Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Droplet microfluidics integrated with machine learning reveals how adipose-derived stem cells modulate endocrine response and tumor heterogeneity in ER + breast cancer.

Ortega Quesada BA., Chauvin C., Martin E., Melvin A.

Prospective Study on Hip, published in Lab Chip (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Lab Chip (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40534514
PMCID
PMC12177710
DOI
10.1039/d5lc00320b
Citations
1

Abstract (original English)

Approximately 70% of breast cancer (BC) diagnoses are estrogen receptor positive (ER + ) with ∼40% of ER + BC patients presenting de novo resistance to endocrine therapy (ET). Recent studies identify the tumor microenvironment (TME) as having a key role in endocrine resistance in which adipose-derived stem cells (ASCs) play an essential role in cancer progression. Prior studies have indicated that ASC characteristics such as age and BMI may play a role in cancer progression. Unfortunately, most studies on ASC-BC cross talk have relied on established two-dimensional (2D) culture systems or the use of conditioned media that cannot replicate the complexity of the three-dimensional (3D) environment. This study used a microfluidic droplet trapping array and thiol-acrylate (TA) hydrogel scaffold to co-culture ER + BC cells and ASCs as individual 3D spheroids (single culture) or organoids (co-culture) in a single device. Endocrine response was interrogated in both spheroids and organoids through the evaluation of proliferation following treatment with the selective estrogen receptor degrader (SERD) fulvestrant (ICI 182 780) followed by 17β-estradiol (E2). Terminal immunostaining for the proliferation marker (Ki67) was performed to evaluate how the presence of ASCs from different donor backgrounds (age and BMI) can modulate endocrine response. Results demonstrated that organoids contai

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansBreast NeoplasmsReceptors, EstrogenFemaleAdipose TissueMachine LearningStem CellsCoculture TechniquesLab-On-A-Chip DevicesMCF-7 Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research